ライフサイエンスコーパス: endothelin receptor antagonist

1 the current practice of adding bosentan, an endothelin receptor antagonist.

2 ral phosphodiesterase-5 inhibitor or an oral endothelin-receptor antagonist.

3 terase type 5 inhibitors, sodium nitrite and endothelin receptor antagonists.

4 bitors, niacin, inhaled carbon monoxide, and endothelin receptor antagonists.

5 mineralocorticoid receptor antagonists, and endothelin receptor antagonists.

6 se biological effects that are unaffected by endothelin receptor antagonists.

7 s of disease-targeted therapy (predominantly endothelin receptor antagonists [47.3%] or phosphodieste

8 gated for the treatment of nmCRPC, including endothelin receptor antagonists and bone-targeted therap

9 -3-methyl-glutaryl-CoA reductase inhibitors, endothelin receptor antagonists and phosphodiesterase ty

10 Conversely, endothelin receptor antagonists and/or KIT blocking anti

11 ple, with phosphodiesterase 5 inhibitors and endothelin receptor antagonists) and, if necessary, the

12 he treatment of PAH: prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase t

13 Endothelin receptor antagonists are first-line therapy f

14 Endothelin-receptor antagonists are in clinical use to t

15 ciated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy.

16 hese findings raise the possibility of using endothelin receptor antagonists as neuroprotective agent

17 These data do not support the use of endothelin receptor antagonists as therapy for ILD secon

18 a 12-month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc-rel

19 R trial assessed the association between the endothelin receptor antagonist atrasentan and pain and p

20 BMS182874, an endothelin receptor antagonist, blocks the effects of ex

21 Treatment with the endothelin receptor antagonist bosentan may be effective

22 liminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercis

23 The endothelin-receptor antagonist bosentan is beneficial in

24 We investigated whether treatment with the endothelin receptor antagonist, bosentan, decreased the

25 The endothelin receptor antagonist BQ-485 (ET(A) selective)

26 Endothelin receptor antagonist (ERA) and phosphodiestera

27 i) may offset fluid retaining effects of the endothelin receptor antagonist (ERA) atrasentan while ef

28 Endothelin receptor antagonists (ERA) and phosphodiester

29 Preclinical studies have demonstrated that endothelin receptor antagonists (ERAs) can reduce or pre

30 Oral endothelin receptor antagonists (ERAs) have been shown t

31 Endothelin receptor antagonists (ERAs) reduce albuminuri

32 Selective endothelin receptor antagonists (ERAs) that target the e

33 Administration of an endothelin receptor antagonist (ETRA, SB 209670) to dogs

34 s sodium-glucose cotransporter 2 inhibitors, endothelin receptor antagonists, glucagon-like peptide 1

35 Atrasentan, an endothelin receptor antagonist, has shown activity in pr

36 Endothelin receptor antagonists have emerged as a novel

37 rable hemodynamic and neurohormonal effects, endothelin receptor antagonists have not improved outcom

38 Endothelin receptor antagonists have revolutionized the

39 mineralocorticoid antagonist and a selective endothelin receptor antagonist, have now been demonstrat

40 In cells treated with endothelin receptor antagonists, hydrogen peroxide scave

41 In many studies, such as the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hyp

42 data support a potential role for selective endothelin receptor antagonists in protecting renal func

43 roenvironment and further support the use of endothelin receptor antagonists in the treatment of inva

44 changes of HPS and the effects of selective endothelin receptor antagonists in vivo were assessed af

45 he efficacy and safety of tezosentan, a dual endothelin receptor antagonist, in patients hospitalized

46 nd safety of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with moderat

47 sess the hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with PHT, in

48 Additionally, infusion of endothelin receptor antagonists into the bursa of wild-t

49 The endothelin receptor antagonist is among the most effecti

50 Aprocitentan, a dual endothelin receptor antagonist, is the first agent from

51 The endothelin receptor antagonist macitentan has demonstrat

52 ar Disease]), we evaluated the effects of an endothelin receptor antagonist, macitentan, in patients

53 Moreover, endothelin receptor antagonists may have a therapeutic r

54 The vasodilator properties of endothelin receptor antagonists may prove valuable thera

55 Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel

56 us epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type

57 y hypoxia but attenuated by either selective endothelin receptor antagonists or oligonucleotides targ

58 were receiving riociguat in combination with endothelin receptor antagonists or prostanoids, or both.

59 hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) pros

60 the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.

61 ials continue to explore new applications of endothelin receptor antagonists, particularly in treatme

62 These effects were prevented by the endothelin receptor antagonist PD145065 (10 microM) and

63 144-363 d) after the initial combination of endothelin receptor antagonist + phosphodiesterase-5 inh

64 erent classes of drugs are now available-ie, endothelin receptor antagonists, phosphodiesterase-5 inh

65 Administration of a nonselective endothelin receptor antagonist provided essentially equi

66 Novel agents, including endothelin receptor antagonists, pyruvate kinase activat

67 Although endothelin-receptor antagonists reduce albuminuria in di

68 udy examined the effects of the nonselective endothelin receptor antagonist SB-209,670, and the less

69 For instance, macitentan and bosentan from endothelin receptor antagonists show major concern while

70 The endothelin receptor antagonist tezosentan did not improv

71 Tezosentan is a dual endothelin receptor antagonist that has been shown to im

72 Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemody

73 Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the

74 the efficacy and safety of bosentan, a dual endothelin-receptor antagonist that can be taken orally,

75 mendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong reco

76 We used a specific endothelin receptor antagonist to determine whether ET-1

77 essed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end poin

78 n of the endothelin system with bosentan, an endothelin receptor antagonist, was strongly protective

79 pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study en

80 tment naive or on background therapy with an endothelin receptor antagonist, were eligible.

81 ts, which have been previously attributed to endothelin receptor antagonists, were more frequent in t

82 as aldosterone synthase inhibitors and dual endothelin receptor antagonists, whereas others may prov

83 g at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.

84 Increasing doses of the endothelin receptor antagonist zibotentan and lower eGFR